Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 21.37 CNY Market Closed
Market Cap: 60.9B CNY
Have any thoughts about
Shanghai Pharmaceuticals Holding Co Ltd?
Write Note

Shanghai Pharmaceuticals Holding Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Pharmaceuticals Holding Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Net Income (Common)
ÂĄ4B
CAGR 3-Years
-9%
CAGR 5-Years
1%
CAGR 10-Years
5%
Sinopharm Group Co Ltd
HKEX:1099
Net Income (Common)
ÂĄ8.7B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
13%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Net Income (Common)
ÂĄ2.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
15%
C
China National Medicines Corp Ltd
SSE:600511
Net Income (Common)
ÂĄ2.2B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
17%
Huadong Medicine Co Ltd
SZSE:000963
Net Income (Common)
ÂĄ3.2B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
17%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Net Income (Common)
ÂĄ1.5B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
9%
No Stocks Found

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
60.9B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a key player in China's healthcare sector, emerged from its roots in the early 1990s to become one of the largest pharmaceutical companies in the country. It operates in two main segments: pharmaceutical manufacturing and distribution. With a strong portfolio of generic and branded medications, the company leverages its extensive distribution network to reach hospitals and pharmacies across China. Shanghai Pharmaceuticals focuses on innovative drug development and has made significant strides in research, particularly in oncology and high-demand therapeutic areas, positioning itself well for growth in a rapidly evolving market. For investors, Shanghai Pharmaceuticals represents a compelling opportunity, not only due to its robust domestic market but also its potential for international expansion. The company's commitment to R&D, alongside strategic partnerships with global pharmaceutical firms, underscores its forward-thinking approach. Additionally, as China's healthcare reforms push for improved access to medicines, Shanghai Pharmaceuticals stands to benefit from increased demand. With a seasoned management team and a solid track record of consistent revenue growth, investors looking for exposure in the burgeoning Asian pharmaceutical landscape may find Shanghai Pharmaceuticals an attractive addition to their portfolios.

Intrinsic Value
46.9 CNY
Undervaluation 54%
Intrinsic Value
Price

See Also

What is Shanghai Pharmaceuticals Holding Co Ltd's Net Income (Common)?
Net Income (Common)
4B CNY

Based on the financial report for Sep 30, 2024, Shanghai Pharmaceuticals Holding Co Ltd's Net Income (Common) amounts to 4B CNY.

What is Shanghai Pharmaceuticals Holding Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%

Over the last year, the Net Income (Common) growth was -12%. The average annual Net Income (Common) growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been -9% over the past three years , 1% over the past five years , and 5% over the past ten years .

Back to Top